Cushing's syndrome in pregnancy treated by ketoconazole: Case report and review of the literature

References

• Nieman L, Cutler G B. Cushing's syndrome. Endocrinology 3rd edn., LJ DeGroot. WB Saunders Company, Philadelphia 1995; 1741–69
   Google Scholar
• Engelhardt D, Weber M M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994; 49: 261–7
   PubMed Web of Science ®Google Scholar
• Buescher M A, McClamrock H D, Adashi E Y. Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79: 130–7
   PubMed Web of Science ®Google Scholar
• Aron D C, Schnall A M, Sheeler L R. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162: 244–52
   PubMed Web of Science ®Google Scholar
• Sheeler L R. Cushing's syndrome and pregnancy. Endocrinol Metab Clin N Am 1994; 23: 619–27
   PubMed Web of Science ®Google Scholar
• Chico A, Manzanares J M, Halperin I, et al. Cushing's disease and pregnancy: report of six cases. Eur J Obstet Gynecol Reprod Biol 1996; 64: 143–6
   PubMed Web of Science ®Google Scholar
• Guilhaume B, Sanson M L, Billaud L, et al. Cushing's syndrome and pregnancy: aetiologies and prognosis in twenty-two patients. Ear J Med 1992; 1: 83–9
   Google Scholar
• Prager D, Braunstein G D. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 1995; 24: 1–14
   PubMed Web of Science ®Google Scholar
• Amado J A, Pesquera C, Gonzalez E M, et al. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J 1990; 66: 221–3
   PubMed Web of Science ®Google Scholar
• Bevan J S, Gough M H, Gillmer MDG, et al. Cushing's syndrome in pregnancy: the timing of definitive treatment. Clin Endocrinol (Oxf.) 1987; 27: 225–33
   PubMed Web of Science ®Google Scholar
• Pricolo V E, Monchik J M, Prinz R A, et al. Management of Cushing's syndrome secondary to adrenal adenoma during pregnancy. Surgery 1990; 108: 1072–8
   PubMed Web of Science ®Google Scholar
• Van der Spuy Z M, Jacobs H S. Management of endocrine disorders in pregnancy. Part II – pituitary, ovarian and adrenal disease. Postgrad Med J 1984; 60: 312–20
   PubMed Web of Science ®Google Scholar
• Hanson T J, Ballonoff L B, Northcutt R C. Amino-glutethimide and pregnancy. J Am Med Assoc 1974; 230: 963–4
   Web of Science ®Google Scholar
• Krieger D T, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing's disease. N Engl J Med 1975; 293: 893–6
   PubMed Web of Science ®Google Scholar
• Kasperlik-Zaluska A, Migdalska B, Hartwig W, et al. Two pregnancies in a woman with Cushing's syndrome treated with cyproheptadine. Case Report. Br J Obstet Gynaecol 1980; 87: 1171–3
   PubMedGoogle Scholar
• Khir ASM, How J, Bewsher P D. Successful pregnancy after cyproheptadine treatment for Cushing's disease. Eur J Obstet Gynecol Reprod Biol 1982; 13: 343–7
   PubMed Web of Science ®Google Scholar
• Gormley MJJ, Hadden D R, Kennedy T L, et al. Cushing's syndrome in pregnancy: treatment with metyrapone. Clin Endocrinol. (Oxf.) 1982; 16: 283–93
   PubMed Web of Science ®Google Scholar
• Connell JMC, Cordiner J, Davies D L, et al. Pregnancy complicated by Cushing's syndrome: potential hazard of metyrapone therapy. Case report. Br J Obstet Gynaecol 1985; 92: 1192–5
   PubMedGoogle Scholar
• Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50: 49–53
   PubMed Web of Science ®Google Scholar
• Aron D C, Schnall A M, Sheeler L R. Spontaneous resolution of Cushing's syndrome after pregnancy. Am J Obstet Gynecol 1990; 162: 472–4
   PubMed Web of Science ®Google Scholar
• Gerl H, Benecke R, Knappe G, et al. Pregnancy and partus in Cushing's disease treated with o,p'-DDD. Acta Endocrinol (Copenh.) 1992; 126(Suppl 4)133
   Google Scholar
• Close C F, Mann M C, Watts J F, et al. ACTH-independent Cushing's syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone. Clin Endocrinol (Oxf.) 1993; 39: 375–9
   PubMed Web of Science ®Google Scholar
• Wallace C, Toth E L, Lewanczuk R Z, et al. Pregnancy-induced Cushing's syndrome in multiple pregnancies. J Clin Endocrinol Metab 1996; 81: 15–21
   PubMed Web of Science ®Google Scholar
• McKenna M J, Linares M, Mellinger R C. Prolonged remission of Cushing's disease following bromocriptine therapy. Henry Ford Hosp Med J 1987; 35: 188–91
   PubMedGoogle Scholar
• Lamberts SWJ, de Lange S A, Stefanko S Z. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab 1982; 54: 286–91
   PubMed Web of Science ®Google Scholar
• Boscaro M, Benato M, Mantero F. Effect of bromocriptine in pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf.) 1983; 19: 485–91
   PubMed Web of Science ®Google Scholar
• Rains C P, Bryson H M, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyper-prolactinaemia and inhibition of lactation. Drugs 1995; 49: 255–79
   PubMed Web of Science ®Google Scholar
• Robert E, Musatti L, Piscitelli G, et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10: 333–7
   PubMed Web of Science ®Google Scholar
• Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocrinol Rev 1986; 7: 409–20
   PubMed Web of Science ®Google Scholar
• Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317: 812–8
   PubMed Web of Science ®Google Scholar
• Pont A, Goldman E S, Sugar A M, et al. Ketoconazole-induced increase in estradiol-testosterone ratio. Arch Intern Med 1985; 145: 1429–31
   PubMed Web of Science ®Google Scholar
• Gal M, Barr I, Lior O, et al. Effect of ketoconazole on steroidogenic human granulosa-luteal cells in culture. Eur J Obstet Gynecol Reprod Biol 1991; 39: 209–14
   PubMed Web of Science ®Google Scholar
• Gal M, Orly J, Barr I, et al. Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro. Fertil Steril 1994; 61: 823–32
   PubMed Web of Science ®Google Scholar
• DiMattina M, Maronian N, Ashby H, et al. Ketoconazole inhibits multiple steroidogenic enzymes involved in androgen biosynthesis in the human ovary. Fertil Steril 1988; 49: 62–5
   PubMed Web of Science ®Google Scholar
• Weber M M, Will A, Adelmann B, et al. Effect of ketoconazole on human ovarian C17,20-desmolase and aromatase. J Steroid Biochem Mol Biol 1991; 38: 213–18
   PubMed Web of Science ®Google Scholar
• Ayub M, Stitch S R. Effects of ketoconazole on placental aromatase, 3β-hyroxysteroid dehydrogenase-isomerase and 17β-hydroxysteroid dehydrogenase. J Steroid Biochem 1986; 25: 981–4
   PubMedGoogle Scholar
• Mason J I, Carr B R, Murry B A. Imidazole antimycotics: selective inhibitors of steroid aromatization and progesterone hydroxylation. Steroids 1987; 50: 179–89
   PubMedGoogle Scholar
• Medda F, Puligheddu P, Parodo G, et al. Short term treatment with ketoconazole: effects on gonadal and adrenal steroidogenesis in women. Clin Exp Obstet Gynecol 1987; 14: 161–6
   PubMedGoogle Scholar
• Wouters W, De Coster R, Goeminne N, et al. Aromatase inhibition by the antifungal ketoconazole. J Steroid Biochem 1988; 30: 387–9
   PubMedGoogle Scholar
• Pepper G, Brenner S H, Gabrilove J L. Ketoconazole use in the treatment of ovarian hyperandrogenism. Fertil Steril 1990; 54: 438–44
   PubMed Web of Science ®Google Scholar
• Angeli A, Frairia R. Ketoconazole therapy in Cushing's disease. Lancet 1985; 1: 821
   PubMed Web of Science ®Google Scholar
• Sonino N, Boscaro M, Merola G, et al. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab 1985; 61: 718–22
   PubMed Web of Science ®Google Scholar
• Loli P, Berselli M E, Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab 1986; 63: 1365–71
   PubMed Web of Science ®Google Scholar
• Sonino N, Boscaro M, Paoletta A, et al. Ketoconazole in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf.) 1991; 35: 347–52
   PubMed Web of Science ®Google Scholar
• Van Tyle J H. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 1984; 4: 343–73
   PubMed Web of Science ®Google Scholar
• Van Cauteren H, Lampo A, Vandenberghe J, et al. Safety aspects of oral antifungal agents. Br J Clin Pract 1990; 71: 47–9
   Google Scholar
• Van Cauteren H, Lampo A, Vandenberghe J, et al. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses 1989; 32: 60–6
   PubMed Web of Science ®Google Scholar
• McGregor J A, Pont A. Contraindication of ketoconazole in pregnancy. Am J Obstet Gynecol 1984; 150: 793–4
   PubMed Web of Science ®Google Scholar
• Miller J W, Crapo L. The medical treatment of Cushing's syndrome. Endocr. Rev 1993; 14: 443–58
   PubMed Web of Science ®Google Scholar